Greater Manchester and Oswestry Sarcoma Service (GMOSS)  
Specialist Sarcoma MDT  

Annual Report 2017  

Host Trust: Manchester University Foundation Trust  
Trust Lead Cancer Clinician: Professor Ajiith Siriwardena  

The Annual Report 2017 has been agreed by:  

The Sarcoma MDT Members who signed off the annual report on 14/03/2018  

Chair of GMOSS MDT Miss Gillian Cribb  
Vice Chair Dr Anand Kirwadi
GMOSS Annual Report 2017

Contents

1. INTRODUCTION
   General .......................................................... 3
   Key Achievements .................................................. 3
   Key Challenges .................................................... 3
2. CHANGES IN 2017 .................................................. 4
3. MDT ACTIVITY
   GMOSS MDT ACTIVITY BY MONTH .................................. 5
   GMOSS MDT ACTIVITY BY SPECIALITY .................................. 6
   GMOSS MDT ACTIVITY BY DIAGNOSIS .................................... 7
   RJAH Bone Tumour Activity for Financial Year 2015/16 ..................... 7
4. Manchester Cancer
   Achievements ...................................................... 8
5. GMOSS MDT Business meetings 2017 .................................... 8
6. MDT ATTENDANCE ..................................................... 9
7. AUDIT AND SERVICE IMPROVEMENT ................................... 10
8. Publications by GMOSS members ....................................... 11
9. PATIENT AND CARER FEEDBACK AND INVOLVEMENT ................. 13
   Patient support initiatives ........................................... 13
   Local patient surveys ................................................. 13
10. RESEARCH AND CLINICAL TRIALS ................................. 14
1. INTRODUCTION

General
The Greater Manchester and Oswestry Sarcoma Service (GMOSS) weekly MDT meeting is held at the Manchester Royal Infirmary, Manchester University Foundation Trust (MFT) with members from RJAH and The Christie joining the meeting via web conference. Cases discussed include all confirmed new, post resection and diagnosis of relapse sarcomas are discussed to formulate a management plan. Cases of fibromatosis and giant cell tumour of bone are also discussed as are other complex benign conditions where multimodal therapy is required.

Diagnostic services are provided at MFT- Manchester Royal Infirmary (soft tissue only) and Robert Jones and Agnes Hunt (RJAH) Hospitals (bone and soft tissue). Core resection services are based at MRI (soft tissue only) and RJAH Hospitals (bone and soft tissue). The Christie Hospital provides plastic surgical support, a retroperitoneal resection service, chemotherapy and radiotherapy services.

The MDT meeting team has been running for several years and had an external peer review undertaken in 2013.

Sarcoma Peer Review is completed yearly and is submitted by MFT
Cancer Outcomes and Services Dataset (COSD) is submitted by MFT
Cancer Wait Times data is submitted separately by the three trusts to Open Exeter.
RJAH Participates in the NHS England Annual Audit Meeting with the other four bone tumour centres. All three trusts participate in the National Cancer Patient Experience Study and results are available on the Quality Health web site

This document shows the activity of the MDT for the calendar year 2016 and includes key changes.

Key Achievements
- RJAH has established a biobank and has been a major contributor of tissue to 100’000 genome project (top trust in 3rd phase of West Midlands rollout of this project)

Key Challenges
- IT Systems at MFT following temporary move of MDT rooms
- Appropriateness of patients submitted for discussion
- Coping with capacity at MFT particularly with newly agreed referral form for sarcomas
- Christies Trial Recruitment. Due to staffing issues, trial recruitment was halted from July 2016 and remained at a very low level in 2017 with only 3 patients entered to trials. We have now partially resolved our staffing issues and are beginning to open new studies for recruitment in 2018.
2. CHANGES IN 2017

CORE AND EXTENDED GMOSS TEAM

Surgical Team
No changes

Radiology
Dr Kulkani has been appointed to CMFT

Pathology
Professor Freemont retired from MFT

Oncology
Dr D Saunders was appointed to Christies
Dr Karup covered for Dr Leahy for 3 months

Clinical Nurse Specialists
RJAH have approval to appoint a Band 6 CNS

Physiotherapy
RJAH has been awarded a 3 year Macmillan Grant for 7 hours/week Band 7 Macmillan Physiotherapist to provide surveillance clinics for bone tumour patients. Mr Geraint Davies will perform these clinics and Mrs Shona Underwood has been appointed to provide the ward cover for these 7 hours.
3. MDT ACTIVITY

The MDT occurs on a Wednesday and is a major job plan commitment for all Consultants involved.

GMOSS MDT ACTIVITY BY MONTH

GMOSS MDT Activity 2017

Month

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Number

80

60

40

20
GMOSS MDT ACTIVITY BY SPECIALITY

GMOSS MDT Activity 2017

<table>
<thead>
<tr>
<th>Month</th>
<th>MED ONC</th>
<th>ORTHO</th>
<th>PLASTICS</th>
<th>RAD ONC</th>
</tr>
</thead>
<tbody>
<tr>
<td>JFMA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MJASOND</td>
<td>30</td>
<td>40</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>JFMA</td>
<td>20</td>
<td>30</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>MJASOND</td>
<td>10</td>
<td>20</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>JFMA</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>MJASOND</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Group

- GMOSS-New
- GMOSS-Other
- GMOSS-Resection
GMOSS MDT ACTIVITY BY DIAGNOSIS

RJAH Bone Tumour Activity for Financial Year 2015/16
(as presented to NHS England audit March 2017)

- Total new patients: 927
- Total follow up patients: 2945
- Suspected primary bone tumour: 351
- Confirmed primary bone tumour: 73
4. MANCHESTER CANCER

The SAG ceased to exist in March 2013 and has been replaced by Manchester Cancer, who met for the first time in June 2014. Mr Amit Kumar was appointed as Manchester Cancer Sarcoma Pathway Clinical Director in June 2017

Achievements

- Finalised Sarcoma referral form with GMOSS members for GM Cancer rollout
- Quarterly Sarcoma pathway board meetings
- Set out terms of reference for Sarcoma pathway board
- Facilitating links with other Sarcoma networks and CNS’s
- Supporting introduction of Recovery Package for GM Cancer patients with Sarcoma
- Future work: Develop education module for Gateway-C, 100K Genome Project

5. GMOSS MDT BUSINESS MEETINGS 2017

Meetings were held and minutes and attendance recorded on the following dates:

Wednesday 29th March

Wednesday 7th June

Wednesday 29th November
6. MDT ATTENDANCE

The table demonstrates the percentage of individual attendance from January 2017 – December 2017 and the cover arrangements that are in place for core members, as set out in the Operational Policy. Attendance is measured as a percentage of MDTs occurring within the year (except for those who started or left during the year where % is of the number of meetings that that person was eligible to attend). A full attendance record is available. There was a total of 51 meetings.

### Orthopaedic Surgeon
- Miss G Cribb: 80%
- Mr P Cool: 76%
- Mr A Paul: 82%
- Mr A Kumar: 69%

### Clinical Oncology
- Dr J Wylie: 75%
- Dr C Coyle: 84%
- Dr D Saunders: 67%

### Medical Oncology
- Dr M Leahy: 78%
- Dr M McCabe: 45%
- Dr L Horsely: 82%
- Registrar: 71%
- Dr Roopa Karup: 59%

### Radiologist
- Dr R Lalam: 63%
- Dr Kirwadi: 69%
- Dr N Winn: 27%
- Dr P Konala: 69%
- Dr S Kulkarni: 50%

### Pathologist
- Prof C Mangham: 47%
- Prof A Freemont: 45%
- Dr P Shenjere: 84%

### CNS
- Sr J Evans: 41%
- Sr C Pemberton: 57%
- Sr S France: 55%
- Sr H Murray: 53%
- Sr A Buchan: 82%
- Sr L Cooper: 78%

### Plastic Surgeon
- Mr D Kosutic: 6%
- Mr D Mowatt: 76%

### Physiotherapist
- Ms M Cumbo: 63%
- Gemma Wilde: 37%

### MDTC
- Gill Furber: 92%
- Other MDTC: 8%
7. AUDIT AND SERVICE IMPROVEMENT

One Stop Sarcoma Clinic MRI– piloted started Oct 17 by AK as part of New Consultant Appointment programme. Service works but capacity particularly with radiology an issue. Continuing pilot, involvement of Transformation team to assess if it is sustainable long term. Review March 18.

The impact and efficacy of surveillance in patients with sarcoma of the extremities.


Complete resolution and remodeling of chronic recurrent multifocal osteomyelitis on MRI and radiographs.

Osteobastoma of the Talus: A case report and review of the literature.

Soft Tissue Tumours – Diagnosis and Pitfalls
Cribb G JTO 2017 Dec;5(4)

Malignant Primary Bone Tumours
Cool P JTO 2017 Dec;5(4)

8. PUBLICATIONS BY GMOSS MEMBERS
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.

Evaluation of biomarkers in the UK phase III VorteX trial confirms importance of tumour hypoxia in soft tissue sarcoma
Laura Forker, Piers Gaunt, Stefano Sioletic, Patrick Shenjere, Joely Irlam, Helen Valentine, David Hughes, Ana Hughes, Lucinda Billingham, Martin Robinson, Catharine West
European Journal of Surgical Oncology 42 (11), S243

The hypoxia marker CA-IX is prognostic in soft tissue sarcoma patients treated in the UK phase III VORTEX trial
L Forker, S Sioletic, P Shenjere, J Irlam, H Valentine, D Hughes, A Hughes, P Gaunt, M Robinson, C West
European Journal of Cancer 61, S70
9. PATIENT AND CARER FEEDBACK AND INVOLVEMENT

Patient support initiatives

Northwest Sarcoma Group
The Northwest Sarcoma group are planning their first Wellness Day in 2018

Oswestry Sarcoma Support Group
The 2nd Health and Wellbeing day was held in October 2017. The support group is advertised in the local Macmillan press and on Sarcoma UK website.

Local patient surveys

Patient Feedback - Nurse Led Clinics at RJAH
A very high level of patient satisfaction was seen. This was presented at the June Business Meeting and a full summary is found in the minutes of this meeting.
“Can shear wave elastography differentiate benign from malignant soft tissue tumours”
Recruitment complete and data being analysed

EuroEwing2012 – randomised controlled trial of first line therapy for ewing sarcoma

reCCUR – randomised controlled trial for therapy in relapsed Ewing sarcoma

EORTC 1202 – phase II trial of carbazitaxel for de-differentiated liposarcoma.

Development of Sarcoma Specific Patient Reported Outcome Measure (Phase 1), with UCH London
(Principal Investigator Mr A Kumar)